Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Takashima

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Uirusu|May 8, 2022
[The innate immune response to SARS-CoV-2]Ken Takashima, Hiroyuki Oshiumi
Oncotarget|September 29, 2015
RIOK3 keeps MDA5 inactiveKen Takashima, Hiroyuki Oshiumi, Tsukasa Seya
Journal of Innate Immunity|October 26, 2017
DNAJB1/HSP40 Suppresses Melanoma Differentiation-Associated Gene 5-Mitochondrial Antiviral Signaling Protein Function in Conjunction with HSP70Ken Takashima, Hiroyuki Oshiumi, Misako Matsumoto, et al.
Biochemical and Biophysical Research Communications|April 9, 2018
TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cellsKen Takashima, Hiroyuki Oshiumi, Misako Matsumoto, et al.
Anatomical Science International|December 23, 2003
Fascial structures and autonomic nerves in the female pelvis: a study using macroscopic slices and their corresponding histologyMitsuharu Tamakawa, Gen Murakami, Ken Takashima, et al.
Cell Reports|April 14, 2015
RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune responseKen Takashima, Hiroyuki Oshiumi, Hiromi Takaki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2026
The nucleolar protein NOP16 suppresses TGF-β-regulated IgA class switch recombination in B cells by regulating AID inductionYohana Silas Mtali, Ken Takashima, Eric Lieberman Greer, et al.
Cancer Science|September 24, 2015
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunityTsukasa Seya, Hiroaki Shime, Yohei Takeda, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|March 13, 2018
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapyTsukasa Seya, Yohei Takeda, Ken Takashima, et al.
EMBO Reports|December 12, 2024
Cholesterol restriction primes antiviral innate immunity via SREBP1-driven noncanonical type I IFNsTasuku Nishimura, Takahisa Kouwaki, Ken Takashima, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Uirusu|May 8, 2022
[The innate immune response to SARS-CoV-2]Ken Takashima, Hiroyuki Oshiumi
Oncotarget|September 29, 2015
RIOK3 keeps MDA5 inactiveKen Takashima, Hiroyuki Oshiumi, Tsukasa Seya
Journal of Innate Immunity|October 26, 2017
DNAJB1/HSP40 Suppresses Melanoma Differentiation-Associated Gene 5-Mitochondrial Antiviral Signaling Protein Function in Conjunction with HSP70Ken Takashima, Hiroyuki Oshiumi, Misako Matsumoto, et al.
Biochemical and Biophysical Research Communications|April 9, 2018
TICAM-1 is dispensable in STING-mediated innate immune responses in myeloid immune cellsKen Takashima, Hiroyuki Oshiumi, Misako Matsumoto, et al.
Anatomical Science International|December 23, 2003
Fascial structures and autonomic nerves in the female pelvis: a study using macroscopic slices and their corresponding histologyMitsuharu Tamakawa, Gen Murakami, Ken Takashima, et al.
Cell Reports|April 14, 2015
RIOK3-mediated phosphorylation of MDA5 interferes with its assembly and attenuates the innate immune responseKen Takashima, Hiroyuki Oshiumi, Hiromi Takaki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 19, 2026
The nucleolar protein NOP16 suppresses TGF-β-regulated IgA class switch recombination in B cells by regulating AID inductionYohana Silas Mtali, Ken Takashima, Eric Lieberman Greer, et al.
Cancer Science|September 24, 2015
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunityTsukasa Seya, Hiroaki Shime, Yohei Takeda, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|March 13, 2018
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapyTsukasa Seya, Yohei Takeda, Ken Takashima, et al.
EMBO Reports|December 12, 2024
Cholesterol restriction primes antiviral innate immunity via SREBP1-driven noncanonical type I IFNsTasuku Nishimura, Takahisa Kouwaki, Ken Takashima, et al.
Pageof 3